Claims for Patent: 7,968,105

Summary for Patent: 7,968,105

Title:	Tuberculosis vaccines comprising antigens expressed during the latent infection phase
Abstract:	The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex (M. tuberculosis, M. bovis, M. africanum, M. microti). The immunogenic composition, vaccine or pharmaceutical composition comprise a fusion polypeptide, which comprises one or more starvation antigens from M. tuberculosis, the units of the fusion polypeptide being M. tuberculosis antigens. Further, the invention is related to the use of a vaccine comprising a fusion polypeptide sequence or nucleic acid sequence of the invention given at the same time as BCG, either mixed with BCG or administered separately at different sites or routes for preparing said immunogenic composition, vaccine, or pharmaceutical composition.
Inventor(s):	Aagaard; Claus (Copenhagen, DK), Vingsbo-Lundberg; Carina (Hollviken, SE), Andersen; Peter (Bronshoj, DK)
Assignee:	Statens Serum Institut (Copenhagen S., DK)
Application Number:	11/993,199
Patent Claims:	1. An immunogenic composition, a vaccine or a pharmaceutical composition comprising a fusion polypeptide comprising the sequence of SEQ ID NO. 12, or a polypeptide comprising at least 80% sequence identity to SEQ. ID. NO. 12. 2. The immunogenic composition, vaccine or pharmaceutical composition comprising a fusion polypeptide according to claim 1, wherein said fusion polypeptide further comprises ESAT6, Ag85B, TB 10.4 or Ag85A, or an analogue thereof. 3. The immunogenic composition, vaccine or pharmaceutical composition according to claim 1 formulated for prophylactic use, therapeutic use, a multiphase vaccine, or to induce a boost in immunity compared to prior to BCG vaccination. 4. The immunogenic composition, vaccine or pharmaceutical composition according to claim 1 formulated for intradermal, transdermal, subcutaneous, intramuscular, or mucosal delivery. 5. The immunogenic composition, vaccine or pharmaceutical composition as claimed in claim 2, wherein the fusion polypeptide comprises 2 different immunogenic polypeptides. 6. The immunogenic composition, vaccine or pharmaceutical composition as claimed in claim 2, wherein the fusion polypeptide comprises 3 different immunogenic polypeptides. 7. The immunogenic composition, vaccine or pharmaceutical composition as claimed in claim 2, wherein the fusion polypeptide comprises 4 different immunogenic polypeptides. 8. The immunogenic composition, vaccine or pharmaceutical composition according to claim 1, wherein said fusion polypeptide further comprises ESAT6 and Ag85A, ESAT6 and Ag85B, TB10 and Ag85A, or TB10 and Ag85B. 9. The immunogenic composition, vaccine or pharmaceutical composition according to claim 8, wherein the fusion polypeptide comprises an amino acid sequence selected from the group consisting of: Ag85B-ESAT6-Rv2660c; Ag85B-TB10.4-Rv2660c; Ag85B-Rv2660c; Ag85A-Rv2660c; Ag85A-ESAT6-Rv2660c; Ag85A-TB10.4-Rv2660c; Rv2660c-Rv2659c; and Ag85B-ESAT6-Rv2660c-Rv2659c. 10. A vaccine or pharmaceutical composition comprising an adjuvant and a fusion polypeptide, wherein the fusion polypeptide comprises the sequence of SEQ ID NO. 12 or a polypeptide comprising at least 80% sequence identity to SEQ. ID. NO. 12. 11. A vaccine or pharmaceutical composition comprising a nucleic acid, which comprises a nucleotide sequence encoding a fusion polypeptide, wherein the fusion polypeptide comprises the sequence of SEQ ID NO. 12 or a polypeptide comprising at least 80% sequence identity to SEQ. ID. NO. 12. 12. The vaccine or pharmaceutical composition according to claim 11, wherein said nucleic acid is formulated for prophylactic use, therapeutic use, a multiphase vaccine, or to be used to boost immunity from prior BCG vaccination. 13. An immunogenic composition, a vaccine or a pharmaceutical composition comprising a fusion polypeptide that comprises the sequence of SEQ. ID. NO. 12. 14. An immunogenic composition, a vaccine or a pharmaceutical composition according to claim 13, formulated for prophylactic use, therapeutic use, a multiphase vaccine, or to induce a boost in immunity compared to prior to BCG vaccination. 15. An immunogenic composition, a vaccine or a pharmaceutical composition as defined in any of claims 13-14 formulated for intradermal, transdermal, subcutaneous, intramuscular, or mucosal delivery. 16. A vaccine or pharmaceutical composition comprising a nucleic acid fragment, which comprises a nucleotide sequence encoding a fusion polypeptide that comprises the sequence of SEQ. ID. NO. 12. 17. A method of improving a BCG vaccine, said method comprising: i) mixing the fusion polypeptide as defined in claim 10 with the BCG vaccine before administration, and injecting the fusion polypeptide together with the BCG vaccine; or ii) keeping the fusion polypeptide as defined in claim 10 and the BCG vaccine separate and administering them at the same time at different sites or through different routes. 18. A method of immunizing an animal against tuberculosis comprising administrating to said animal the immunogenic composition, vaccine or pharmaceutical composition according to claim 1. 19. The method according to claim 18, wherein the immunogenic composition, vaccine or pharmaceutical composition is administrated before sign of infection is present. 20. The method according to claim 18, wherein the immunogenic composition, vaccine or pharmaceutical composition is administered to treat established infections with mycobacteria. 21. A method of boosting a previous BCG vaccinated person comprising administrating the immunogenic composition, vaccine or pharmaceutical composition according to claim 1.

Details for Patent 7,968,105

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Teknika Llc	N/A	bcg vaccine	For Injection	103050	06/21/1989		2025-06-23